Federated Hermes
CHRS icon

Federated Hermes’s Coherus Oncology CHRS Stock Holding History

Federated Hermes’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.62K Buy
3,916
+1,976
+102% +$3.51K ﹤0.01% 1870
2025
Q4 		$2.75K Buy
1,940
+1,461
+305% +$2.13K ﹤0.01% 1949
2025
Q3 		$786 Buy
+479
New +$533 ﹤0.01% 2081
2024
Q4 		– Sell
-582
Closed -$605 – 2091
2024
Q3 		$605 Buy
+582
New +$798 ﹤0.01% 1990
2022
Q4 		– Sell
-4,223
Closed -$41K – 2178
2022
Q3 		$41K Buy
4,223
+1,498
+55% +$15.2K ﹤0.01% 1696
2022
Q2 		$20K Sell
2,725
-2,214
-45% -$19.3K ﹤0.01% 1763
2022
Q1 		$64K Buy
4,939
+708
+17% +$9K ﹤0.01% 1709
2021
Q4 		$68K Sell
4,231
-6,900
-62% -$121K ﹤0.01% 1754
2021
Q3 		$179K Buy
+11,131
New +$163K ﹤0.01% 1680
2021
Q2 		– Sell
-161
Closed -$2K – 2220
2021
Q1 		$2K Sell
161
-49,905
-100% -$847K ﹤0.01% 2116
2020
Q4 		$870K Buy
50,066
+425
+0.9% +$7.57K ﹤0.01% 1372
2020
Q3 		$910K Buy
+49,641
New +$923K ﹤0.01% 1268
2019
Q4 		– Sell
-329,979
Closed -$6.68M – 2222
2019
Q3 		$6.68M Sell
329,979
-227,259
-41% -$4.54M 0.02% 689
2019
Q2 		$12.3M Buy
+557,238
New +$9.68M 0.03% 507
2019
Q1 		– Sell
-1,348
Closed -$12K – 2155
2018
Q4 		$12K Sell
1,348
-134,723
-99% -$1.56M ﹤0.01% 1846
2018
Q3 		$2.25M Buy
136,071
+82,334
+153% +$1.46M 0.01% 1049
2018
Q2 		$752K Buy
53,737
+52,226
+3,456% +$748K ﹤0.01% 1368
2018
Q1 		$17K Buy
1,511
+80
+6% +$875 ﹤0.01% 1785
2017
Q4 		$13K Sell
1,431
-38
-3% -$407 ﹤0.01% 1833
2017
Q3 		$20K Buy
+1,469
New +$19.4K ﹤0.01% 1753
2016
Q1 		– Sell
-284,000
Closed -$6.52M – 2110
2015
Q4 		$6.52M Sell
284,000
-126,200
-31% -$3.25M 0.02% 516
2015
Q3 		$8.22M Hold
410,200
– – 0.03% 468
2015
Q2 		$11.9M Buy
+410,200
New +$10.4M 0.04% 433

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Federated Hermes's CHRS Position: Q1 2026 in Review

Federated Hermes increased its Coherus Oncology (CHRS) stake by 102% in Q1 2026, buying an estimated $3.51K and bringing the position to 3,916 shares worth $6.62K. The position accounts for ﹤0.01% of the portfolio, ranked #1870.

Federated Hermes first reported a position in CHRS in Q2 2015 and has held it in 23 quarters since. The position peaked at $12.3M in Q2 2019. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Federated Hermes held 3,916 shares of Coherus Oncology worth $6.62K as of Q1 2026.
  • Federated Hermes bought 1,976 Coherus Oncology shares in Q1 2026, an estimated $3.51K.
  • Coherus Oncology made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1870 holding.
  • Federated Hermes first reported a position in Coherus Oncology in Q2 2015 and has held it in 23 quarters since.
  • Federated Hermes's Coherus Oncology position peaked at $12.3M in Q2 2019.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.